Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure

BACKGROUND: Anthracyclines are widely used in the treatment of childhood cancer. One of the well-recognized side-effects of anthracycline therapy is dose-dependent cardiomyopathy that may progress to heart failure (HF) years after completion of cancer-directed therapy. This study will evaluate the e...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cardiovasc Disord
Auteurs principaux: Armenian, Saro H., Hudson, Melissa M., Chen, Ming Hui, Colan, Steven D., Lindenfeld, Lanie, Mills, George, Siyahian, Aida, Gelehrter, Sarah, Dang, Ha, Hein, Wendy, Green, Daniel M., Robison, Leslie L., Wong, F. Lennie, Douglas, Pamela S., Bhatia, Smita
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Study Protocol
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5050602/
https://ncbi.nlm.nih.gov/pubmed/27716152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12872-016-0364-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires